Recent Updates
Recently added Catalysts
FTH Positive Sentiment

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

Monday, October 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Faeth Therapeutics has announced that it will present preclinical data on its lead program, PIKTOR, at the ESMO Congress 2026 in Madrid. The presentation is scheduled for October 23 and aims to support the ongoing development of PIKTOR in the FTH-PIK-101 Phase 1b/2 trial. This event underscores the company's commitment to advancing cancer therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Faeth is advancing its lead program, PIKTOR.
  • Presentation at a prestigious event like ESMO highlights credibility.
  • Preclinical data may enhance the understanding of PIKTOR's efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~34 mo
Minimal dilution risk
Lead asset
Serabelisib
Phase 1 · HR+ HER2- Breast Cancer

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will present preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.The poster will be presented on Friday, October 23, and will showcase preclinical data intended to inform the ongoing development of PIKTOR in the FTH-PIK-101 Phase 1b/2 trial

Frequently Asked Questions

What is the focus of Faeth's presentation at ESMO 2026?

Faeth will present preclinical data on its lead program, PIKTOR.

When will Faeth present its data at ESMO 2026?

The presentation is scheduled for Friday, October 23.

What trial is PIKTOR associated with?

PIKTOR is part of the FTH-PIK-101 Phase 1b/2 trial.

Where is the ESMO Congress 2026 taking place?

The ESMO Congress 2026 will be held in Madrid, Spain.

ShareAdd on Google
Tags: FTH Faeth Therapeutics PIKTOR breast cancer ESMO 2026
Last updated: Oct 19, 2026

Biotech snapshot

Cash runway
$186M liquidity · $5M/mo burn
~34 mo
Minimal dilution risk
Lead asset
SerabelisibPhase 1
HR+ HER2- Breast Cancer →